KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Emergent BioSolutions (EBS) EBIAT (2016 - 2025)

Emergent BioSolutions' EBIAT history spans 15 years, with the latest figure at -$54.6 million for Q4 2025.

  • For Q4 2025, EBIAT fell 74.44% year-over-year to -$54.6 million; the TTM value through Dec 2025 reached $52.6 million, up 127.6%, while the annual FY2025 figure was $52.6 million, 127.6% up from the prior year.
  • EBIAT reached -$54.6 million in Q4 2025 per EBS's latest filing, down from $51.2 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $193.1 million in Q4 2021 to a low of -$283.1 million in Q2 2024.
  • Average EBIAT over 5 years is -$44.5 million, with a median of -$35.8 million recorded in 2021.
  • Peak YoY movement for EBIAT: plummeted 10480.0% in 2022, then surged 655.56% in 2025.
  • A 5-year view of EBIAT shows it stood at $193.1 million in 2021, then plummeted by 134.7% to -$67.0 million in 2022, then increased by 26.12% to -$49.5 million in 2023, then surged by 36.77% to -$31.3 million in 2024, then tumbled by 74.44% to -$54.6 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's EBIAT are -$54.6 million (Q4 2025), $51.2 million (Q3 2025), and -$12.0 million (Q2 2025).